The role of stem cell transplantation in chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) generally follows an indolent clinical course and usually occurs in the elderly. However, the disease is heterogeneous with some patients having a more aggressive clinical course and short survival. Although the role of fludarabine in combination with other chemotherapy drugs and/or monoclonal antibody therapy appears promising, to date chemotherapy has not been curative in this disease. At present, the only potential cure for CLL appears to be stem cell transplantation (SCT), but its role in the management of CLL has not been established. In particular, patient selection for consideration of SCT, timing of SCT in the clinical course of CLL, selection of autologous versus allogeneic SCT, use of nonmyeloablative regimens, and exploitation of the graft-versus-leukemia (GVL) effect are currently under investigation.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
V
V
Rizouli
J g
Jg
Gribben Jg
D000367:Age Factors; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D013997:Time Factors; D014182:Transplantation, Autologous